Disclaimer
CompoundIQ publishes research summaries for informational and educational purposes only. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. Always consult a licensed healthcare provider. Many compounds listed are research chemicals not approved for human use.
BPC-157
Also known as: Body Protection Compound-157, Bepecin, PL 14736, PL-10
BPC-157 is a synthetic pentadecapeptide derived from a protective protein found in human gastric juice. It has demonstrated broad healing and cytoprotective effects in numerous animal studies, including tendon, ligament, muscle, and gut tissue repair. Despite strong preclinical data, controlled human clinical trials remain limited.
Risk Level
Low RiskDifficulty
Beginner| CAS Number | 137525-51-0 |
| Class | Peptide |
| Category | Well-Known Peptides |
Mechanism of Action
BPC-157 modulates the nitric oxide system and upregulates growth factor expression including VEGF, EGF, and FGF, promoting angiogenesis and tissue repair. It interacts with the dopaminergic and GABAergic systems, contributing to its gastroprotective and wound-healing effects. The peptide also appears to counteract organ damage caused by NSAIDs and alcohol through stabilization of endothelial function.
Dosing Research
Typical research dosing ranges from 200-800 mcg/day administered subcutaneously or intramuscularly. Oral dosing at 250-500 mcg twice daily has been explored for gastrointestinal applications. Cycles commonly run 4-8 weeks.
Side Effects & Risks
Generally considered well-tolerated in animal models with a favorable safety profile. Reported side effects are minimal but may include nausea, dizziness, and injection site reactions. Long-term human safety data is lacking.
Research Studies
Related compounds
Semaglutide
PeptideSemaglutide is a GLP-1 receptor agonist approved for type 2 diabetes (Ozempic) and chronic weight management (Wegovy). Clinical trials demonstrated average weight loss of 15-17% of body weight. It has become one of the most widely discussed medications in modern weight management.
Tirzepatide
PeptideTirzepatide is a dual GLP-1/GIP receptor agonist approved for type 2 diabetes (Mounjaro) and obesity (Zepbound). It has demonstrated unprecedented weight loss efficacy in clinical trials, with participants losing up to 20-25% of body weight. It represents the cutting edge of pharmaceutical weight management.
Liraglutide
PeptideLiraglutide is a GLP-1 receptor agonist approved for type 2 diabetes (Victoza, 1.8 mg) and obesity (Saxenda, 3.0 mg). It was the first GLP-1 agonist approved specifically for weight management. While effective, it has been largely superseded by semaglutide and tirzepatide in terms of weight loss efficacy.
PT-141
PeptidePT-141 (bremelanotide) is a synthetic cyclic heptapeptide melanocortin receptor agonist that was FDA-approved in 2019 as Vyleesi for the treatment of hypoactive sexual desire disorder in premenopausal women. Unlike PDE5 inhibitors, it acts centrally through the melanocortin system to increase sexual desire rather than just facilitating erection mechanics. It is the only FDA-approved on-demand treatment targeting central sexual arousal pathways.
Disclaimer
CompoundIQ publishes research summaries for informational and educational purposes only. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. Always consult a licensed healthcare provider. Many compounds listed are research chemicals not approved for human use.